Karo Bio has decided to discontinue the development program for eprotirome after an animal study demonstrated unwanted effects following long-term exposure. The company will terminate its ongoing Phase II and III studies in dyslipidemia. This termination has prompted Karo Bio to reassess its previous decision to spin off its preclinical activities, which are focused on nuclear receptors, into an autonomous subsidiary. In October 2011, the firm reported that it aimed to restructure activities into two companies: one focused on eprotirome and the other organized around its knowledge in nuclear receptors. While the preclinical part was intended to be sold to new owners so that Karo Bio cound focus on the eprotirome program, the company will now concentrate operations on the preclinical projects.
